CAMBRIDGE, MA—Alnylam Pharmaceuticals has signed on with BioMed Realty Trust for a 295,000 square foot lease at 675 West Kendall in Cambridge, a class A laboratory and office space in Kendall Square.
Alnylam is leading the translation of RNA interference (RNAi), as a new class of innovative medicines, with a core focus on RNAi therapeutics toward genetically defined targets for the treatment of serious, life-threatening diseases with limited treatment options. This growing life science company will occupy all the rentable space available on the six floors of 675 West Kendall when the lease with the current tenant, Vertex Pharmaceuticals, ends in May 2018.
"BioMed Realty has built our business on helping life science companies be successful by providing the laboratory and office platform for companies like Alnylam to conduct breakthrough science that help patients throughout the world," said Bill Kane, SVP for BioMed Realty. "We will welcome Alnylam to their new home, and provide them our unique real estate expertise to ensure they have the best facility to create life-changing treatments for patients."
Continue Reading for Free
Register and gain access to:
- Breaking commercial real estate news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical coverage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
David Phillips
David Phillips is a Chicago-based freelance writer and consultant with more than 20 years experience in business and community news. He also has extensive reporting experience in the food manufacturing industry for national trade publications.
